nitinol and Breast-Neoplasms

Purpose To evaluate outcomes of Savi Scout (Cianna Medical, Aliso Viejo, Calif) reflector-guided localization and excision of breast lesions by analyzing reflector placement, localization, and removal, along with target excision and rates of repeat excision (referred to as re-excision). Materials and Methods A single-institution retrospective review of 100 women who underwent breast lesion localization and excision by using the Savi Scout surgical guidance system from June 2015 to May 2016 was performed. By using image guidance 0-8 days before surgery, 123 nonradioactive, infrared-activated, electromagnetic wave reflectors were percutaneously inserted adjacent to or within 111 breast targets. Twenty patients had two or three reflectors placed for bracketing or for localizing multiple lesions, and when ipsilateral, they were placed as close as 2.6 cm apart. Target and reflector were localized intraoperatively by one of two breast surgeons who used a handpiece that emitted infrared light and electromagnetic waves. Radiographs of the specimen and pathologic analysis helped verify target and reflector removal. Target to reflector distance was measured on the mammogram and radiograph of the specimen, and reflector depth was measured on the mammogram. Pathologic analysis was reviewed. Re-excision rates and complications were recorded. By using statistics software, descriptive statistics were generated with 95% confidence intervals (CIs) calculated. Results By using sonographic (40 of 123; 32.5%; 95% CI: 24.9%, 41.2%) or mammographic (83 of 123; 67.5%; 95% CI: 58.8% 75.1%) guidance, 123 (100%; 95% CI: 96.4%, 100%) reflectors were placed. Mean mammographic target to reflector distance was 0.3 cm. All 123 (100%; 95% CI: 96.4%, 100%) targets and reflectors were excised. Pathologic analysis yielded 54 of 110 malignancies (49.1%; 95% CI: 39.9%, 58.3%; average, 1.0 cm; range, 0.1-5 cm), 32 high-risk lesions (29.1%; 95% CI: 21.4%, 38.2%), and 24 benign lesions (21.8%; 95% CI: 115.1%, 30.4%). Four of 54 malignant cases (7.4%; 95% CI: 2.4%, 18.1%) demonstrated margins positive for cancer that required re-excision. Five of 110 radiographs of the specimen (4.5%; 95% CI: 1.7%, 10.4%) demonstrated increased distance between the target and reflector distance of greater than 1.0 cm (range, 1.1-2.6 cm) compared with postprocedure mammogram the day of placement, three of five were associated with hematomas, two of five migrated without identifiable cause. No related postoperativ

Topics: Adult; Aged; Aged, 80 and over; Alloys; Breast Neoplasms; Electromagnetic Phenomena; Equipment Design; Female; Fiducial Markers; Humans; Infrared Rays; Mammography; Ultrasonography, Mammary

Hemorrhage caused by tumor invasion of the axillary artery is a rare, but serious complication. A 70-year-old female with a history of inflammatory breast cancer was diagnosed with hypovolemic shock caused by arterial bleeding into the left axilla. After successful reanimation an emergency arteriography was performed. The bleeding site was localized in the proximal part of the axillary artery. A self-expanding endoluminal graft was positioned across the lesion. The final angiography showed a correct placement of the stent with excellent distal flow, and no signs of bleeding. On the seventh day, the patient was discharged with ambulatory follow up.

Topics: Aged; Alloys; Angioplasty, Balloon; Axilla; Axillary Artery; Blood Vessel Prosthesis Implantation; Breast Neoplasms; Carcinoma; Female; Hemorrhage; Humans; Neoplasm Invasiveness; Radiography; Shock; Stents

Evaluation of ultrasound-guided percutaneous marking of breast cancer using an "O-Twist Marker" (BARD GmbH, Karlsruhe, Germany) in patients undergoing neoadjuvant chemotherapy. In the event of complete remission, the lesion of interest can be missed after completion of therapy. In these cases marking of the tumor site is essential.. We monitored patients with breast cancer proven by biopsy who were undergoing neoadjuvant chemotherapy with ultrasound. In cases in which the follow-up ultrasound examination after the second chemotherapy cycle showed a significant tumor mass reduction (> 30 %), we pinpointed the lesion with an ultrasound-guided "O-Twist Marker". The position of the marker was documented by ultrasound and mammography. Between January and November 2006, we marked 7 patients.. The visibility of the marker was excellent on mammography, but only moderate on ultrasound. The marker did not cause any imaging interference. The instrument was easy to operate. We did not detect any migration of the marker. In 3/7 patients it would have been possible to locate the remaining tumor tissue after the completion of neoadjuvant chemotherapy without the marking. In 4/7 cases the clip was very useful or even essential for preoperative site determination.. The use of "O-Twist Marker" is a reliable and effective technique for locating breast cancer sites in remission during neoadjuvant chemotherapy. The visibility of the marker on ultrasound should be improved. In 57 % of the cases tumor marking was advantageous for surgical procedures.

Topics: Adult; Alloys; Biocompatible Materials; Biopsy; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Mammography; Middle Aged; Monitoring, Physiologic; Neoadjuvant Therapy; Treatment Outcome; Ultrasonography, Mammary

To evaluate the treatment of malignant biliary stenoses and occlusions using a new stent.. In a prospective study, 25 patients with malignant obstructive jaundice were treated with SMART(R) stents. The handling and the quality of stent expansion were documented. Stent function was assessed 2 - 4 days after intervention by cholangiography and laboratory tests. A follow-up was performed three months, after stent placement.. All lesions were treated successfully, with a total of 35 stents implanted. In 14 patients a further balloon dilatation was performed after stent placement (8 - 10 mm diameter/ 40 - 80 mm length). The mean serum bilirubin level decreased significantly from 11.6 mg/dl to 4.6 mg/dl after intervention (p < 0.05). The follow-up showed a mean serum bilirubin level at 4.0 mg/dl. In 4 cases (16 %) a further intervention (PTCD or stent) was performed. Six patients died due to tumor progression. The stents proved to be patent in 79 % (n = 15) of patients alive at the time of follow-up.. Placement of the SMART stent for the therapy of malignant biliary lesions yields good technical and clinical results.

Topics: Aged; Aged, 80 and over; Alloys; Bilirubin; Breast Neoplasms; Carcinoma, Hepatocellular; Cholestasis; Colonic Neoplasms; Drainage; Female; Follow-Up Studies; Humans; Klatskin Tumor; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiography; Reoperation; Stents; Stomach Neoplasms; Time Factors